Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-γ, activation

T. Matsui, Shoichi Yamagishi, S. Ueda, K. Nakamura, T. Imaizumi, M. Takeuchi, Hiroyoshi Inoue

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Interaction between advanced glycation end-products (AGEs) and their receptor (RAGE) plays a central role in diabetic nephropathy pathogenesis. Pathophysiological crosstalk between the AGEs-RAGE system and angiotensin II (Ang II) is also involved in this disease. This study investigated the role of proliferator-activated receptor-γ (PPAR-γ)-modulating activity on inhibition of monocyte chemoattractant protein (MCP-1) expression. Telmisartan, an Ang II type 1 receptor blocker, downregulated RAGE mRNA and inhibited superoxide generation and MCP-1 gene expression in mesangial cells; these processes were blocked by GW9662, a PPAR-γ inhibitor. Candesartan, an Ang II type 1 receptor blocker, did not suppress AGEs-induced superoxide generation. Telmisartan and the antioxidant, N-acetylcysteine, completely inhibited AGEs-induced MCP-1 overproduction by mesangial cells. These results suggest that telmisartan inhibits AGEs-signalling to MCP-1 expression in mesangial cells by downregulating RAGE gene expression and subsequent oxidative stress generation via PPAR-γ activation. This study has demonstrated a unique benefit of telmisartan in that it may function as an anti-inflammatory agent against AGEs via PPAR-γ activation and may play a protective role in diabetic nephropathy.

Original languageEnglish
Pages (from-to)482-489
Number of pages8
JournalJournal of International Medical Research
Volume35
Issue number4
Publication statusPublished - 2007 Jul
Externally publishedYes

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Peroxisome Proliferator-Activated Receptors
Advanced Glycosylation End Products
Mesangial Cells
Chemokine CCL2
Down-Regulation
Chemical activation
Diabetic Nephropathies
Gene expression
Superoxides
Monocyte Chemoattractant Proteins
Gene Expression
Oxidative stress
Acetylcysteine
Crosstalk
Angiotensin II
Oxidative Stress
Anti-Inflammatory Agents
Antioxidants
telmisartan

Keywords

  • Advanced glycation end-products (AGEs)
  • Candesartan
  • Diabetic nephropathy
  • GW9662
  • Monocyte chemoattractant protein-1 (MCP-1)
  • Peroxisome proliferator-activated receptor-γ (PPAR-γ) oxidative stress
  • Telmisartan

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{e6657ca9dbe8406f876bfc6df4302fcf,
title = "Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-γ, activation",
abstract = "Interaction between advanced glycation end-products (AGEs) and their receptor (RAGE) plays a central role in diabetic nephropathy pathogenesis. Pathophysiological crosstalk between the AGEs-RAGE system and angiotensin II (Ang II) is also involved in this disease. This study investigated the role of proliferator-activated receptor-γ (PPAR-γ)-modulating activity on inhibition of monocyte chemoattractant protein (MCP-1) expression. Telmisartan, an Ang II type 1 receptor blocker, downregulated RAGE mRNA and inhibited superoxide generation and MCP-1 gene expression in mesangial cells; these processes were blocked by GW9662, a PPAR-γ inhibitor. Candesartan, an Ang II type 1 receptor blocker, did not suppress AGEs-induced superoxide generation. Telmisartan and the antioxidant, N-acetylcysteine, completely inhibited AGEs-induced MCP-1 overproduction by mesangial cells. These results suggest that telmisartan inhibits AGEs-signalling to MCP-1 expression in mesangial cells by downregulating RAGE gene expression and subsequent oxidative stress generation via PPAR-γ activation. This study has demonstrated a unique benefit of telmisartan in that it may function as an anti-inflammatory agent against AGEs via PPAR-γ activation and may play a protective role in diabetic nephropathy.",
keywords = "Advanced glycation end-products (AGEs), Candesartan, Diabetic nephropathy, GW9662, Monocyte chemoattractant protein-1 (MCP-1), Peroxisome proliferator-activated receptor-γ (PPAR-γ) oxidative stress, Telmisartan",
author = "T. Matsui and Shoichi Yamagishi and S. Ueda and K. Nakamura and T. Imaizumi and M. Takeuchi and Hiroyoshi Inoue",
year = "2007",
month = "7",
language = "English",
volume = "35",
pages = "482--489",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "4",

}

TY - JOUR

T1 - Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-γ, activation

AU - Matsui, T.

AU - Yamagishi, Shoichi

AU - Ueda, S.

AU - Nakamura, K.

AU - Imaizumi, T.

AU - Takeuchi, M.

AU - Inoue, Hiroyoshi

PY - 2007/7

Y1 - 2007/7

N2 - Interaction between advanced glycation end-products (AGEs) and their receptor (RAGE) plays a central role in diabetic nephropathy pathogenesis. Pathophysiological crosstalk between the AGEs-RAGE system and angiotensin II (Ang II) is also involved in this disease. This study investigated the role of proliferator-activated receptor-γ (PPAR-γ)-modulating activity on inhibition of monocyte chemoattractant protein (MCP-1) expression. Telmisartan, an Ang II type 1 receptor blocker, downregulated RAGE mRNA and inhibited superoxide generation and MCP-1 gene expression in mesangial cells; these processes were blocked by GW9662, a PPAR-γ inhibitor. Candesartan, an Ang II type 1 receptor blocker, did not suppress AGEs-induced superoxide generation. Telmisartan and the antioxidant, N-acetylcysteine, completely inhibited AGEs-induced MCP-1 overproduction by mesangial cells. These results suggest that telmisartan inhibits AGEs-signalling to MCP-1 expression in mesangial cells by downregulating RAGE gene expression and subsequent oxidative stress generation via PPAR-γ activation. This study has demonstrated a unique benefit of telmisartan in that it may function as an anti-inflammatory agent against AGEs via PPAR-γ activation and may play a protective role in diabetic nephropathy.

AB - Interaction between advanced glycation end-products (AGEs) and their receptor (RAGE) plays a central role in diabetic nephropathy pathogenesis. Pathophysiological crosstalk between the AGEs-RAGE system and angiotensin II (Ang II) is also involved in this disease. This study investigated the role of proliferator-activated receptor-γ (PPAR-γ)-modulating activity on inhibition of monocyte chemoattractant protein (MCP-1) expression. Telmisartan, an Ang II type 1 receptor blocker, downregulated RAGE mRNA and inhibited superoxide generation and MCP-1 gene expression in mesangial cells; these processes were blocked by GW9662, a PPAR-γ inhibitor. Candesartan, an Ang II type 1 receptor blocker, did not suppress AGEs-induced superoxide generation. Telmisartan and the antioxidant, N-acetylcysteine, completely inhibited AGEs-induced MCP-1 overproduction by mesangial cells. These results suggest that telmisartan inhibits AGEs-signalling to MCP-1 expression in mesangial cells by downregulating RAGE gene expression and subsequent oxidative stress generation via PPAR-γ activation. This study has demonstrated a unique benefit of telmisartan in that it may function as an anti-inflammatory agent against AGEs via PPAR-γ activation and may play a protective role in diabetic nephropathy.

KW - Advanced glycation end-products (AGEs)

KW - Candesartan

KW - Diabetic nephropathy

KW - GW9662

KW - Monocyte chemoattractant protein-1 (MCP-1)

KW - Peroxisome proliferator-activated receptor-γ (PPAR-γ) oxidative stress

KW - Telmisartan

UR - http://www.scopus.com/inward/record.url?scp=34547884217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547884217&partnerID=8YFLogxK

M3 - Article

C2 - 17697525

AN - SCOPUS:34547884217

VL - 35

SP - 482

EP - 489

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 4

ER -